Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1645 1654 1658 1675
This examiner grants 33% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17597925 | ANTIMICROBIAL THERAPY THROUGH THE COMBINATION OF PORE-FORMING AGENTS AND HISTONES | Final Rejection | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 17583549 | Composition for and Method of Improving Tissue Performance | Non-Final OA | OHIO STATE INNOVATION FOUNDATION |
| 17006591 | PROTEASE SENSITIVE GVPC AND RELATED GAS VESICLE GENE CLUSTERS, EXPRESSION SYSTEMS, CONSTRUCTS, VECTORS, GENETIC CIRCUITS, CELLS, COMPOSITIONS, METHODS AND SYSTEMS FOR CONTRAST-ENHANCED IMAGING | Non-Final OA | California Institute of Technology |
| 18252073 | Peptide Inhibitors of Human Mitochondrial Fission Protein 1 and Methods of Use | Non-Final OA | The Medical College of Wisconsin, Inc. |
| 18337091 | PREPAKAGED POLYMERASE CHAIN REACTION (PCR) REAGENT FOR NUCLEIC ACID AMPLIFICATION AND METHOD THEREOF | Final Rejection | Xiamen University |
| 18044962 | PTPSIGMA-FC FUSION PROTEIN AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Final Rejection | IUCF-HYU (INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY) |
| 18551271 | NOVEL PEPTIDE-OLIGONUCLEOTIDE CONJUGATE AND USE THEREOF | Non-Final OA | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY |
| 18253231 | PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA)-TARGETED PRODRUG FOR SELECTIVE KILLING OF CELLS EXPRESSING PSMA | Non-Final OA | The Johns Hopkins University |
| 18339817 | NOVEL CYCLIC PEPTIDES BASED ON NANOBIOSTRUCTURAL CONTROL, PEPTIDESOMES WITH CORE/SHELL STRUCTURE COMPRISING SAME, AND USES THEREOF | Non-Final OA | UIF (University Industry Foundation), Yonsei University |
| 17633631 | METHODS OF MAKING INCRETIN ANALOGS | Final Rejection | ELI LILLY AND COMPANY |
| 16972800 | Compositions of Transforming Growth Factor-Beta Type III Receptor and Uses for Ossification | Final Rejection | Emory University |
| 18279931 | PHOTOCAGED CITRULLINE ANALOGS AND METHODS FOR SITE-SPECIFIC INCORPORATION OF CITRULLINE INTO PROTEINS | Non-Final OA | University of Massachusetts |
| 17919507 | COMPOSITIONS AND METHODS FOR PREVENTING OR REDUCING THE EFFECTS OF INFECTIONS BY CORONAVIRUSES THAT BIND THE EXTRACELLULAR DOMAIN OF THE ACE2 RECEPTOR | Final Rejection | The Administrators of the Tulane Educational Fund |
| 18664616 | SILK FIBROIN-CONTAINING COMPOSITION AND METHODS OF USE THEREOF | Non-Final OA | Georgetown University |
| 17620467 | COMPOSITES AND USES THEREOF | Non-Final OA | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. |
| 17631072 | COMPOSITION FOR PROMOTING GROWTH OR SUPPRESSING DECREASE OF MESENCHYMAL STEM CELLS | Final Rejection | OSAKA UNIVERSITY |
| 16198019 | CARDIAC FIBROBLAST-DERIVED EXTRACELLULAR MATRIX AND INJECTABLE FORMULATIONS THEREOF FOR TREATMENT OF ISCHEMIC DISEASE OR INJURY | Final Rejection | Wisconsin Alumni Research Foundation |
| 18259092 | METHODS OF TREATING, DIAGNOSING AND PREDICTING PROGNOSIS OF SEPSIS | Non-Final OA | University of Rochester |
| 18269716 | METHOD FOR PRODUCING LIPIDIC PEPTIDE | Non-Final OA | NISSAN CHEMICAL CORPORATION |
| 17606174 | METHOD FOR PRODUCING PEPTIDE COMPOUND | Final Rejection | NISSAN CHEMICAL CORPORATION |
| 17282883 | METHODS OF REDUCING TYPE 2 CYTOKINE-MEDIATED INFLAMMATION USING NEUROMEDIN PEPTIDES | Final Rejection | Rutgers, The State University of New Jersey |
| 18272549 | DUAL-ADMINISTRATION METHODS FOR TREATING RESPIRATORY DISTRESS | Non-Final OA | THE TRUSTEES OF THE STEVENS INSTITUTE OF TECHNOLOGY |
| 17251079 | NON-VITAL WHEAT PROTEIN AND ITS PRODUCTION PROCESS | Final Rejection | ROQUETTE FRERES |
| 18612989 | PHARMACEUTICAL USE | Final Rejection | ENLITISA (SHANGHAI) PHARMACEUTICAL CO., LTD. |
| 17788506 | METHOD FOR SYNTHESIZING PEPTIDE COMPOUND | Final Rejection | CHUGAI SEIYAKU KABUSHIKI KAISHA |
| 18386904 | MICRONEEDLE SYSTEM FOR APPLYING GLUCAGON-LIKE PEPTIDE ANALOGUES | Final Rejection | LTS LOHMANN THERAPIE-SYSTEME AG |
| 17608463 | PEPTIDE DERIVATIVES AND CONJUGATES THEREOF FOR TREATING CANCER | Final Rejection | The University of Sydney |
| 18432185 | TREATMENT OF HYPOPARATHYROIDISM | Final Rejection | Entera Bio Ltd. |
| 15549425 | TREATMENT OF OSTEOPOROSIS | Final Rejection | Entera Bio Ltd. |
| 15549418 | TREATMENT OF BONE FRACTURES AND DEFECTS | Final Rejection | Entera Bio Ltd. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy